All In Biotech

NDA 022287 · Takeda Pharms USA

Dexilant

Dexlansoprazole · Oral · Proton Pump Inhibitor

Last checked: Nov 20, 2026Latest source record: Jul 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Jan 30, 2009

Approved uses

5

Original approval plus efficacy supplements

Registered trials

288

83 Phase 3, 12 recruiting

FAERS reports

41,708

33,723 serious, 3,737 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 17, 2025.

DEXILANT is a proton pump inhibitor (PPI) indicated in patients 12 years of age and older for: Healing of all grades of erosive esophagitis (EE). ( 1.1 ) Maintenance of healed EE and relief of heartburn. ( 1.2 ) Treatment of symptomatic non-erosive gastroesophageal reflux disease (GERD). ( 1.3 ) 1.1 Healing of Erosive Esophagitis DEXILANT ® is indicated in patients 12 years of age and older for healing of all grades of erosive esophagitis (EE) for up to eight weeks. 1.2 Maintenance of Healed Erosive Esophagitis and Relief of Heartburn DEXILANT is indicated in patients 12 years of age and older to maintain healing of EE and relief of heartburn for up to six months in adults and 16 weeks in patients 12 to 17 years of age. 1.3 Treatment of Symptomatic Non-Erosive Gastroesophageal Reflux Disease DEXILANT is indicated in patients 12 years of age and older for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks.

Mechanism: Dexlansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the (H + , K + )-ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, dexlansoprazole has been characterized as a gastric proton-pump inhibitor, in that it blocks the final step of acid production.

Therapeutic areas: Gastroenterology and liver

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • DEXILANT · DEXLANSOPRAZOLE 30MG · CAPSULE, DELAYED RELEASE, ORAL · Prescription · TE AB
  • DEXILANT · DEXLANSOPRAZOLE 60MG · CAPSULE, DELAYED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Dexlansoprazole" as an intervention, any sponsor and status, largest first.

All 288 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • chronic kidney disease16,102
  • acute kidney injury7,811
  • renal failure6,722
  • end stage renal disease4,888
  • renal injury4,339
  • drug ineffective2,627
  • fatigue2,442
  • off label use2,345
  • nausea2,244
  • tubulointerstitial nephritis2,191
  • diarrhoea2,006
  • headache1,972

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20081
20092
2010114
2011375
2012710
2013707
2014989
20151,641
20162,105
20171,672
201813,439
20197,819
20202,724
20212,416
20221,915
20231,556
20241,362
20251,292
2026869

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Dexilant (Dexlansoprazole)

2024 spending

$41.0M

Beneficiaries

20,798

86,176 claims

Per beneficiary

$1,972

$9.73 per unit

View as table
YearSpending
2020$651,674,922
2021$675,684,020
2022$407,784,107
2023$87,349,224
2024$41,017,762

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 42 on PubMed

Sponsor: Takeda

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.